Showing results (81-90 of 105) with videos related to

Sort By:
Pageof 11
Annals of the Rheumatic Diseases|July 21, 2021
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunityDaniel Mrak, Selma Tobudic, Maximilian Koblischke, et al.
Infection|June 15, 2020
Successful management of the first reported case in Austria of COVID-19 with ARDST Seitz, W Hoepler, L Weseslindtner, et al.
American Journal of Surgery|December 20, 2016
A randomized, blinded, multicenter trial of a gentamicin vancomycin gel (DFA-02) in patients undergoing abdominal surgeryElliott Bennett-Guerrero, Scott M Berry, Sergio D Bergese, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|June 16, 2014
Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI studyThomas J Povsic, John P Vavalle, John H Alexander, et al.
American Heart Journal|September 11, 2013
Embedding a randomized clinical trial into an ongoing registry infrastructure: unique opportunities for efficiency in design of the Study of Access site For Enhancement of Percutaneous Coronary Intervention for Women (SAFE-PCI for Women)Connie N Hess, Sunil V Rao, David F Kong, et al.
Frontiers in Medicine|December 2, 2020
Dynamics of CD4 T Cell and Antibody Responses in COVID-19 Patients With Different Disease SeverityMaximilian Koblischke, Marianna T Traugott, Iris Medits, et al.
Gastroenterology|December 24, 2011
Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infectionSandra Beinhardt, Judith H Aberle, Michael Strasser, et al.
Respiratory Medicine|April 19, 2026
Long-term Safety of the Pfizer-BioNTech COVID-19 Vaccine: Results from the HERO-Together StudyEmily C O'Brien, Cherise Wong, Jesse M DeLaRosa, et al.
Circulation|July 28, 2010
First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary interventionMauricio G Cohen, Drew A Purdy, Joseph S Rossi, et al.
European Heart Journal|August 4, 2012
A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trialThomas J Povsic, John P Vavalle, Laura H Aberle, et al.
Pageof 11